Rational use of plasma protein and tissue binding data in drug design

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8238-8248

  Liu, Xingrong ^a   Wright, Matthew ^a   Hop, Cornelis E C A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; PROTEIN BINDING;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN TISSUE; BRAIN TISSUE BINDING; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; INTRINSIC CLEARANCE; LIVER CLEARANCE; MEMBRANE PERMEABILITY; NONHUMAN; PLASMA PROTEIN BINDING; VOLUME OF DISTRIBUTION; BRAIN; METABOLISM; PHARMACOKINETICS; TISSUE DISTRIBUTION;

BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DESIGN; HUMANS; PHARMACOKINETICS; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 84908381840     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5007935     Document Type: Article

References (64)

1. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity J. Pharm. Sci. 2003, 92, 2236-2248
2. Gleeson, M. P. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis J. Med. Chem. 2007, 50, 101-112
3. Brunton, L.; Lazo, J.; Parker, K. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11 th ed.; McGraw-Hill: New York, 2006.
4. Liu, X.; Chen, C. Strategies to optimize brain penetration in drug discovery Curr. Opin. Drug Discovery Dev. 2005, 8, 505-512
5. Trainor, G. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 2, 51-64
6. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A. On the rate and extent of drug delivery to the brain Pharm. Res. 2008, 25, 1737-1750
7. Lin, J. H. CSF as a surrogate for assessing CNS exposure: an industrial perspective Curr. Drug Metab. 2008, 9, 46-59
8. Schmidt, S.; Gonzalez, D.; Derendorf, H. Significance of protein binding in pharmacokinetics and pharmacodynamics J. Pharm. Sci. 2010, 99, 1107-1122
9. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
10. Yang, J.; Jamei, M.; Yeo, K. R.; Rostami-Hodjegan, A.; Tucker, G. T. Misuse of the well-stirred model of hepatic drug clearance Drug Metab. Dispos. 2007, 35, 501-502
11. Banker, M. J.; Clark, T. H.; Williams, J. A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding J. Pharm. Sci. 2003, 92, 967-974
12. Kariv, I.; Cao, H.; Oldenburg, K. R. Development of a high throughput equilibrium dialysis method J. Pharm. Sci. 2001, 90, 580-587
13. Fung, E. N.; Chen, Y. H.; Lau, Y. Y. Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry J. Chromatogr., B: Anal. Technol. Biomed Life Sci. 2003, 795, 187-194
14. Wan, H.; Rehngren, M. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry J. Chromatogr., A 2006, 1102, 125-134
15. Aureli, L.; Cruciani, G.; Cesta, M. C.; Anacardio, R.; De Simone, L.; Moriconi, A. Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach J. Med. Chem. 2005, 48, 2469-2479
16. Wang, J.; Krudy, G.; Xie, X. Q.; Wu, C.; Holland, G. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion J. Chem. Inf. Model. 2006, 46, 2674-2683
17. Yamazaki, K.; Kanaoka, M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds J. Pharm. Sci. 2004, 93, 1480-1494
18. Kratochwil, N. A.; Huber, W.; Muller, F.; Kansy, M.; Gerber, P. R. Predicting plasma protein binding of drugs: a new approach Biochem. Pharmacol. 2002, 64, 1355-1374
19. Kalvass, J. C.; Maurer, T. S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery Biopharm. Drug Dispos. 2002, 23, 327-338
20. Summerfield, S. G.; Lucas, A. J.; Porter, R. A.; Jeffrey, P.; Gunn, R. N.; Read, K. R.; Stevens, A. J.; Metcalf, A. C.; Osuna, M. C.; Kilford, P. J.; Passchier, J.; Ruffo, A. D. Toward an improved prediction of human in vivo brain penetration Xenobiotica 2008, 38, 1518-1535
21. Son, D. S.; Osabe, M.; Shimoda, M.; Kokue, E. Contribution of alpha 1-acid glycoprotein to species difference in lincosamides-plasma protein binding kinetics J. Vet. Pharmacol. Ther. 1998, 21, 34-40
22. Endo, H.; Yoshida, H.; Hasegawa, M.; Ohmi, N.; Horiuchi, N.; Hamada, Y.; Higuchi, S. Stereoselectivity and species difference in plasma protein binding of KE-298 and its metabolites Biol. Pharm. Bull. 2001, 24, 800-805
23. Hong, Y.; Tang, Y.; Zeng, S. Enantioselective plasma protein binding of propafenone: mechanism, drug interaction, and species difference Chirality 2009, 21, 692-698
24. Clarke, H. J.; Gregoire, F.; Ma, F.; Martin, R.; Zhao, S.; Lavan, B. E. Cross-species differential plasma protein binding of MBX-102/JNJ39659100: a novel PPAR-gamma agonist PPAR Res. 2008, 2008, 1-10
25. Hunt, K. W.; Cook, A. W.; Watts, R. J.; Clark, C. T.; Vigers, G.; Smith, D.; Metcalf, A. T.; Gunawardana, I. W.; Burkard, M.; Cox, A. A.; Geck Do, M. K.; Dutcher, D.; Thomas, A. A.; Rana, S.; Kallan, N. C.; DeLisle, R. K.; Rizzi, J. P.; Regal, K.; Sammond, D.; Groneberg, R.; Siu, M.; Purkey, H.; Lyssikatos, J. P.; Marlow, A.; Liu, X.; Tang, T. P. Spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid beta in a higher species J. Med. Chem. 2013, 56, 3379-3403
26. Boffito, M.; Back, D. J.; Blaschke, T. F.; Rowland, M.; Bertz, R. J.; Gerber, J. G.; Miller, V. Protein binding in antiretroviral therapies AIDS Res. Hum. Retroviruses 2003, 19, 825-835
27. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus Virology 1998, 250, 255-262
28. Friden, M.; Gupta, A.; Antonsson, M.; Bredberg, U.; Hammarlund-Udenaes, M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids Drug Metab. Dispos. 2007, 35, 1711-1719
29. Chu, X.; Korzekwa, K.; Elsby, R.; Fenner, K.; Galetin, A.; Lai, Y.; Matsson, P.; Moss, A.; Nagar, S.; Rosania, G. R.; Bai, J. P.; Polli, J. W.; Sugiyama, Y.; Brouwer, K. L. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver Clin. Pharmacol. Ther. 2013, 94, 126-141
30. Mateus, A.; Matsson, P.; Artursson, P. Rapid measurement of intracellular unbound drug concentrations Mol. Pharmaceutics 2013, 10, 2467-2478
31. Pfeifer, N. D.; Harris, K. B.; Yan, G. Z.; Brouwer, K. L. Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue Drug Metab. Dispos. 2013, 41, 1949-1956
32. Bass, L.; Robinson, P.; Bracken, A. J. Hepatic elimination of flowing substrates: the distributed model J. Theor. Biol. 1978, 72, 161-184
33. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance J. Pharmacokinet. Biopharm. 1977, 5, 625-653
34. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation J. Pharmacokinet. Biopharm. 1977, 5, 655-680
35. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation J. Pharmacokinet. Biopharm. 1977, 5, 681-699
36. Roberts, M. S.; Rowland, M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations J. Pharmacokinet. Biopharm. 1986, 14, 227-260
37. Roberts, M. S.; Rowland, M. A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity J. Pharmacokinet. Biopharm. 1986, 14, 261-288
38. Roberts, M. S.; Rowland, M. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics J. Pharmacokinet. Biopharm. 1986, 14, 289-308
39. Forker, E. L.; Luxon, B. Hepatic transport kinetics and plasma disappearance curves: distributed modeling versus conventional approach Am. J. Physiol. 1978, 235, E648-E660
40. Berezhkovskiy, L. M. On the influence of protein binding on pharmacological activity of drugs J. Pharm. Sci. 2010, 99, 2153-2165
41. Borchardt, R. T.; Smith, P. L.; Wilson, G. Models for Assessing Drug Absorption and Metabolism, 8 th ed.; Plenum Press: New York, 1996; Vol. 8.
42. Liu, X.; Chen, C.; Hop, C. E. Do we need to optimize plasma protein and tissue binding in drug discovery? Curr. Top Med. Chem. 2011, 11, 450-466
43. Jones, D. B.; Morgan, D. J.; Mihaly, G. W.; Webster, L. K.; Smallwood, R. A. Discrimination between the venous equilibrium and sinusoidal models of hepatic drug elimination in the isolated perfused rat liver by perturbation of propranolol protein binding J. Pharmacol. Exp. Ther. 1984, 229, 522-526
44. Smallwood, R. H.; Morgan, D. J.; Mihaly, G. W.; Jones, D. B.; Smallwood, R. A. Effect of plasma protein binding on elimination of taurocholate by isolated perfused rat liver: comparison of venous equilibrium, undistributed and distributed sinusoidal, and dispersion models J. Pharmacokinet. Biopharm. 1988, 16, 377-396
45. Nagase, S.; Shimamune, K.; Shumiya, S. Albumin-deficient rat mutant Science 1979, 205, 590-591
46. Miida, H.; Arakawa, S.; Shibaya, Y.; Honda, K.; Kiyosawa, N.; Watanabe, K.; Manabe, S.; Takasaki, W.; Ueno, K. Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR) J. Toxicol. Sci. 2008, 33, 349-361
47. Ito, T.; Takahashi, M.; Sudo, K.; Sugiyama, Y. Marked strain differences in the pharmacokinetics of an alpha4beta1 integrin antagonist, 4-[1-[3-chloro-4-[ N -(2-methylphenyl)-ureido]phenylacetyl]-(4 S)-fluoro-(2 S)-pyrrolidine-2-yl]-methoxybenzoic acid (D01-4582), in Sprague-Dawley rats are associated with albumin genetic polymorphism J. Pharmacol. Exp. Ther. 2007, 320, 124-132
48. Benet, L. Z.; Hoener, B. A. Changes in plasma protein binding have little clinical relevance Clin. Pharmacol. Ther. 2002, 71, 115-121
49. Toutain, P. L.; del Castillo, J. R.; Bousquet-Melou, A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics Res. Vet. Sci. 2002, 73, 105-114
50. Blakey, G. E.; Nestorov, I. A.; Arundel, P. A.; Aarons, L. J.; Rowland, M. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat J. Pharmacokinet. Biopharm. 1997, 25, 277-312
51. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds Drug Metab. Dispos. 2008, 36, 1385-1405
52. Gibaldi, M.; Perrier, D. Apparent volume of distribution. In Pharmacokinetics, 2 nd ed.; Marcel Dekker: New York, 1982; Vol. 15, pp 199-219.
53. Lombardo, F.; Obach, R. S.; Shalaeva, M. Y.; Gao, F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics J. Med. Chem. 2004, 47, 1242-1250
54. Lombardo, F.; Obach, R. S.; Shalaeva, M. Y.; Gao, F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data J. Med. Chem. 2002, 45, 2867-2876
55. Boxenbaum, H.; Battle, M. Effective half-life in clinical pharmacology J. Clin. Pharmacol. 1995, 35, 763-766
56. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept Chem. Biodiversity 2009, 6, 2030-2049
57. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development J. Pharmacol. Exp. Ther. 2008, 325, 349-356
58. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery J. Med. Chem. 2013, 56, 2-12
59. Hammarlund-Udenaes, M.; Bredberg, U.; Friden, M. Methodologies to assess brain drug delivery in lead optimization Curr. Top Med. Chem. 2009, 9, 148-162
60. Hammarlund-Udenaes, M.; Paalzow, L. K.; de Lange, E. C. Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method Pharm. Res. 1997, 14, 128-134
61. Maurer, T. S.; Debartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice Drug Metab. Dispos. 2005, 33, 175-181
62. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab. Dispos. 2005, 33, 165-174
63. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen Osuna, M.; Hammond, B.; Tang, S. P.; Hersey, A.; Spalding, D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain J. Pharmacol. Exp. Ther. 2006, 316, 1282-1290
64. Liu, X.; Vilenski, O.; Kwan, J.; Apparsundaram, S.; Weikert, R. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats Drug Metab. Dispos. 2009, 37, 1548-1556